The role of protein p16(INK4a) in glottic laryngeal squamous cell carcinoma
Jazyk angličtina Země Švýcarsko Médium print-electronic
Typ dokumentu časopisecké články
- MeSH
- dospělí MeSH
- glottis metabolismus patologie MeSH
- inhibitor p16 cyklin-dependentní kinasy metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru metabolismus mortalita patologie MeSH
- lymfatické metastázy MeSH
- míra přežití MeSH
- nádorové biomarkery metabolismus MeSH
- nádory hrtanu metabolismus mortalita patologie MeSH
- následné studie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- senioři MeSH
- spinocelulární karcinom metabolismus mortalita sekundární MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- inhibitor p16 cyklin-dependentní kinasy MeSH
- nádorové biomarkery MeSH
Head and neck squamous cell cancer (HNSCC) includes tumors of various anatomical sites sharing the common etiological factors. However some differences in pathogenesis and prognosis of HNSCC have been hitherto documented. Laryngeal squamous cell carcinoma (LSCC) is one the most common type of the head and neck cancer. The majority of laryngeal cancers are located in the glottic area. P16 was recently documented to be important prognostic marker in many tumors including HNSCC. The aim of our study was to assess the significance of p16 expression in glottic LSCC. Fifty eight patients after surgical treatment of the glottic LSCC were enrolled in the retrospective study. The p16 expression was immunohistochemically detected and semiquantitatively evaluated in tumor tissue. The results were statistically correlated with clinical and pathological parameters. Protein p16 was expressed in glottic LSCC of 15 patients (25.9 %). Statistically significant higher p16 overexpression was proven in non-smokers in comparison with smokers (75 % versus 18 %; p =0.003). Recurrent cancer was diagnosed in 8 patients (13.8 %), and all these tumors were p16 negative. Our study shows, that p16 expression in glottic LSCC especially in subgroup of non-smokers might be promising prognosticator of better clinical outcome in routine practice. The p16 status did not statistically correlate with cervical lymph node metastases or with grading and staging of cancers, respectively. The preliminary results suggest that p16 overexpression in glottic LSCC may identify patients at low risk of disease recurrence. However, the pathobiology of this tumor as well as predictive role of p16 expression in laryngeal cancer still remains to be better elucidated.
Zobrazit více v PubMed
J Oncol. 2012;2012:739461 PubMed
Int J Cancer. 2010 Dec 15;127(12):2893-917 PubMed
Anticancer Res. 2007 Mar-Apr;27(2):979-84 PubMed
Exp Cell Res. 2001 Mar 10;264(1):42-55 PubMed
Pathol Res Pract. 2008;204(8):545-52 PubMed
Laryngoscope. 2009 Aug;119(8):1531-7 PubMed
J Laryngol Otol. 2004 Sep;118(9):676-80 PubMed
Mod Pathol. 2011 Nov;24(11):1413-20 PubMed
Laryngoscope. 2013 Jan;123(1):164-70 PubMed
Anticancer Res. 2007 Jan-Feb;27(1A):283-8 PubMed
Clin Exp Metastasis. 2008;25(8):887-92 PubMed
Braz J Med Biol Res. 2012 Dec;45(12):1327-33 PubMed
Int J Epidemiol. 2011 Apr;40(2):489-502 PubMed
Braz Oral Res. 2011 Jan-Feb;25(1):34-41 PubMed
Folia Histochem Cytobiol. 2011;49(1):34-40 PubMed
J Med Virol. 2010 May;82(6):1017-23 PubMed
Ann Diagn Pathol. 2012 Apr;16(2):91-9 PubMed
ORL J Otorhinolaryngol Relat Spec. 2007;69(1):30-6 PubMed
Clin Otolaryngol. 2006 Aug;31(4):259-66 PubMed
Am J Surg Pathol. 2010 Aug;34(8):1088-96 PubMed
Int J Oncol. 2011 Jul;39(1):51-9 PubMed
Eur Arch Otorhinolaryngol. 2011 Nov;268(11):1541-7 PubMed
Laryngoscope. 2012 Sep;122 Suppl 2:S13-33 PubMed
Gastroenterol Hepatol. 2007 Dec;30(10):592-6 PubMed
J Cell Physiol. 2012 Jan;227(1):233-8 PubMed
Clin Biochem. 2008 Sep;41(13):1059-66 PubMed
Am J Pathol. 1997 Dec;151(6):1767-74 PubMed
Am J Clin Pathol. 2006 Aug;126(2):284-93 PubMed
Acta Otolaryngol. 1998 Sep;118(5):754-8 PubMed
Hematol Oncol Clin North Am. 2008 Dec;22(6):1125-42, vii PubMed
Am J Pathol. 1998 Dec;153(6):1741-8 PubMed
Laryngoscope. 2010 Sep;120(9):1788-94 PubMed
Neoplasma. 2012;59(4):398-408 PubMed
Pathol Oncol Res. 2011 Sep;17(3):721-7 PubMed
Virchows Arch. 2003 Jan;442(1):1-7 PubMed
Head Neck. 2011 Apr;33(4):581-6 PubMed
N Engl J Med. 2010 Jul 1;363(1):24-35 PubMed
J Natl Cancer Inst. 1995 Oct 18;87(20):1524-9 PubMed
Am J Surg Pathol. 2011 Sep;35(9):1343-50 PubMed
Curr Genomics. 2009 Jun;10(4):231-9 PubMed
Mod Pathol. 2013 Feb;26(2):223-31 PubMed
J Clin Pathol. 1997 Jun;50(6):509-12 PubMed
Med Oral Patol Oral Cir Bucal. 2010 Sep 01;15(5):e681-4 PubMed
Mod Pathol. 2009 May;22(5):686-98 PubMed
Cancer Res. 1994 Mar 1;54(5):1156-8 PubMed
Acta Otolaryngol. 1994 May;114(3):348-51 PubMed
Ann Oncol. 2010 Oct;21(10):1961-1966 PubMed
Histopathology. 2012 May;60(6):982-91 PubMed
Otolaryngol Head Neck Surg. 2012 May;146(5):730-8 PubMed
CA Cancer J Clin. 2013 Jan;63(1):57-81 PubMed
Genet Mol Res. 2009 Dec 23;8(4):1509-18 PubMed
Oncogene. 1999 Jul 8;18(27):3930-5 PubMed
